While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > ACADEMIA
ACADEMIA
- Architect of Oncolytic Virus Therapy Looks to Its Use in All Solid Cancers in 5 Years
June 25, 2021
- Reproductive Medicine Society Issues Fertility Treatment Guidelines, Prods Careful Design for Health Coverage
June 25, 2021
- Japan Researchers Produce “Super Neutralizing Antibodies”
June 17, 2021
- As Aducanumab Decision Nears, Health Economist Stresses Need for Broad Value Evaluation, Target Patient Criteria
June 4, 2021
- Cancer Patients Have Lower Antibody Titers against Coronavirus: NCC
June 3, 2021
- NCC, 5 Other Institutions Forge Genome Cohort of 366,000 People
May 28, 2021
- Hematologist Sees No Swelling Costs from 2 New CAR-T Contenders in Japan; Will Competition Drive Down Prices?
May 28, 2021
- New AMR Prevention Technology Could Contribute to Antiviral Development; Application to COVID-19 Meds Expected: Professor
May 17, 2021
- Olumiant Expected to Shorten Time to Recovery from COVID-19: Infection Expert
May 12, 2021
- No. of New Lung Cancer Patients Fell 6.6% in 2020 amid COVID-19: Survey
May 11, 2021
- Survival Rate Declines for Some Cancers Even after 5 Years: NCC
April 28, 2021
- New RA Guidelines Upgrade Position of JAK Inhibitors, Biosimilars on Equal Footing with Reference Products
April 26, 2021
- 3 Existing Drugs Show Inhibitory Effects for SARS-CoV-2 in iPSC Screening
April 8, 2021
- Tokushukai Weighs Switches from Nichi-Iko Products after Biz Suspension Order
March 15, 2021
- COVID-19 Vaccination Should Be Avoided in Patients with Severe Hypersensitivity to PEG: Allergy Society
March 3, 2021
- Thorough Medication Guidance through Regional Collaboration Important for Rybelsus: Professor
February 22, 2021
- NCGM to Initiate Clinical Study of Convalescent Plasma Therapy for COVID-19 as Early as February
January 28, 2021
- Lynparza Got Prostate Cancer OK, but Reimbursement Issues Remain for CDx Costs: Professor
January 22, 2021
- Antitussive Cloperastine Strongly Attacks Cisplatin-Resistant Cancer Cells: Research Group
January 22, 2021
- Japan Reports Mother-to-Infant Cervical Tumor Transmission via Amniotic Fluids
January 7, 2021
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…